Protective Effect of Tadalafil on the Functional and Structural Changes of the Rat Ventral Prostate Caused by Chronic Pelvic Ischemia

Overview

Journal Prostate

Date 2014 Oct 21

PMID 25327615

Citations 12

Authors

Mona Zarifpour

Masanori Nomiya

Norifumi Sawada

Karl-Erik Andersson

Affiliations

Soon will be listed here.

Abstract

Background: The etiology of Benign Prostatic Hyperplasia (BPH), a common among aged men, is not fully understood, however, in addition to androgens and aging, chronic ischemia has been proposed to contribute. Using an established rat model, we investigated whether chronic ischemia alters the structural and functional properties of the ventral rat prostate, and whether phosphodiesterase type 5 (PDE5) inhibitor (tadalafil) may have a protective action.

Methods: Adult male Sprague-Dawley rats were divided into control, arterial endothelial injury (AI), and AI with tadalafil treatment (AI-tadalafil) groups. AI and AI-tadalafil groups underwent endothelial injury of the iliac arteries and received a 2% cholesterol diet following AI. AI-tadalafil rats were treated with tadalafil (2 mg/kg/day) orally for 8 weeks after AI. The control group received a regular diet. After 8 weeks, animals were sacrificed, and pharmacological and morphological studies on prostate tissues were performed.

Results: Iliac arteries from AI rats displayed neo-intimal formation and luminal occlusion, an effect that was not prevented by tadalafil treatment. In the AI group, there was an obvious epithelial atrophy and a statistically significant increase in collagen fibers compared with the controls. Immunohistochemically, there was an up-regulation of smooth muscle α-actin (SMA). Contractile responses of prostate strips to KCl, electrical field stimulation (EFS), and phenylephrine (PE) were significantly higher after AI than in controls. Chronic treatment with tadalafil prevented the increase in contractile responses in ischemic tissue, and decreased the collagen deposition compared with the AI group.

Conclusions: In this rat model, chronic pelvic ischemia caused distinct functional and morphological changes in the prostate. Prostatic tissue from ischemic animals showed an increased contractile response to electrical and pharmacological stimulation, an increase in SMA, and an increased deposition of collagen. All these changes could be prevented by treatment with the PDE5 inhibitor, tadalafil, suggesting an involvement of cyclic guanosine monophosphate (cGMP).

Citing Articles

Revisiting the issue of "beach balls" in holmium laser enucleation of prostate: clinical and histological characterization.

Herzberg H, Savin Z, Fahoum I, Lifshitz K, Gildor O, Veredgorn Y World J Urol. 2024; 42(1):201.

PMID: 38546885 DOI: 10.1007/s00345-024-04902-9.

Risk Factors of Salvage Procedure for Refractory Morcellation During Holmium Laser Enucleation of the Prostate.

Yoon H, Chung D, Cho S, Cho M, Paick J, Oh S Int Neurourol J. 2023; 27(3):200-206.

PMID: 37798887 PMC: 10556432. DOI: 10.5213/inj.2346076.038.

Understanding human aging and the fundamental cell signaling link in age-related diseases: the middle-aging hypovascularity hypoxia hypothesis.

Phua T Front Aging. 2023; 4:1196648.

PMID: 37384143 PMC: 10293850. DOI: 10.3389/fragi.2023.1196648.

Tissue Kallikrein Protects Rat Prostate against the Inflammatory Damage in a Chronic Autoimmune Prostatitis Model via Restoring Endothelial Function in a Bradykinin Receptor B2-Dependent Way.

Zhang M, Lin D, Luo C, Wei P, Cui K, Chen Z Oxid Med Cell Longev. 2022; 2022:1247806.

PMID: 35154561 PMC: 8826119. DOI: 10.1155/2022/1247806.

A phosphodiesterase 5 inhibitor, tadalafil, suppresses stromal predominance and inflammation in a rat model of nonbacterial prostatitis.

Sugimoto M, Zhang X, Ueda N, Tsunemori H, Taoka R, Hayashida Y BMC Urol. 2019; 19(1):99.

PMID: 31646996 PMC: 6806527. DOI: 10.1186/s12894-019-0525-x.

References

Sagawa K, Aikawa K, Nomiya M, Ogawa S, Akaihata H, Takahashi N . Impaired detrusor contractility in a rat model of chronic bladder ischemia. Urology. 2013; 81(6):1379.e9-14. DOI: 10.1016/j.urology.2013.02.013. View

Nomiya M, Burmeister D, Sawada N, Campeau L, Zarifpour M, Keys T . Prophylactic effect of tadalafil on bladder function in a rat model of chronic bladder ischemia. J Urol. 2012; 189(2):754-61. DOI: 10.1016/j.juro.2012.07.141. View

Polovina M, Potpara T . Endothelial dysfunction in metabolic and vascular disorders. Postgrad Med. 2014; 126(2):38-53. DOI: 10.3810/pgm.2014.03.2739. View

Miller M . Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. Ann Pharmacother. 2013; 47(2):278-83. DOI: 10.1345/aph.1R528. View

Giuliano F, Uckert S, Maggi M, Birder L, Kissel J, Viktrup L . The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. Eur Urol. 2012; 63(3):506-16. DOI: 10.1016/j.eururo.2012.09.006. View

Kedia G, Uckert S, Jonas U, Kuczyk M, Burchardt M . The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol. 2008; 26(6):603-9. DOI: 10.1007/s00345-008-0303-y. View

Uckert S, Oelke M . Phosphodiesterase (PDE) inhibitors in the treatment of lower urinary tract dysfunction. Br J Clin Pharmacol. 2011; 72(2):197-204. PMC: 3162649. DOI: 10.1111/j.1365-2125.2010.03828.x. View

Fowkes F, Rudan D, Rudan I, Aboyans V, Denenberg J, McDermott M . Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382(9901):1329-40. DOI: 10.1016/S0140-6736(13)61249-0. View

Gacci M, Corona G, Vignozzi L, Salvi M, Serni S, De Nunzio C . Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int. 2014; 115(1):24-31. DOI: 10.1111/bju.12728. View

10.

Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G . Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res. 2006; 19(2):200-7. DOI: 10.1038/sj.ijir.3901513. View

11.

Klotz T, Mathers M, Bloch W, Nayal W, Engelmann U . Nitric oxide based influence of nitrates on micturition in patients with benign prostatic hyperplasia. Int Urol Nephrol. 2000; 31(3):335-41. DOI: 10.1023/a:1007174102953. View

12.

Aikawa K, Yokota T, Okamura H, Yamaguchi O . Endogenous nitric oxide-mediated relaxation and nitrinergic innervation in the rabbit prostate: the changes with aging. Prostate. 2001; 48(1):40-6. DOI: 10.1002/pros.1079. View

13.

Bloch W, Klotz T, Loch C, Schmidt G, Engelmann U, Addicks K . Distribution of nitric oxide synthase implies a regulation of circulation, smooth muscle tone, and secretory function in the human prostate by nitric oxide. Prostate. 1997; 33(1):1-8. DOI: 10.1002/(sici)1097-0045(19970915)33:1<1::aid-pros1>3.0.co;2-p. View

14.

Nomiya M, Yamaguchi O, Andersson K, Sagawa K, Aikawa K, Shishido K . The effect of atherosclerosis-induced chronic bladder ischemia on bladder function in the rat. Neurourol Urodyn. 2011; 31(1):195-200. DOI: 10.1002/nau.21073. View

15.

Lythgoe C, McVary K . The use of PDE-5 inhibitors in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia. Curr Urol Rep. 2013; 14(6):585-94. DOI: 10.1007/s11934-013-0373-2. View

16.

De Nunzio C, Aronson W, Freedland S, Giovannucci E, Parsons J . The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2011; 61(3):560-70. DOI: 10.1016/j.eururo.2011.11.013. View

17.

Higashi Y, Kihara Y, Noma K . Endothelial dysfunction and hypertension in aging. Hypertens Res. 2012; 35(11):1039-47. DOI: 10.1038/hr.2012.138. View

18.

Schauer I, Rowley D . The functional role of reactive stroma in benign prostatic hyperplasia. Differentiation. 2011; 82(4-5):200-10. PMC: 3179838. DOI: 10.1016/j.diff.2011.05.007. View

19.

Girman C, Jacobsen S, Guess H, Oesterling J, Chute C, Panser L . Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol. 1995; 153(5):1510-5. DOI: 10.1016/s0022-5347(01)67448-2. View

20.

Morelli A, Sarchielli E, Comeglio P, Filippi S, Mancina R, Gacci M . Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011; 8(10):2746-60. DOI: 10.1111/j.1743-6109.2011.02416.x. View